Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
InflaRx NV | IFRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.39 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 1.14 - 5.20 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 1.39 | USD |
InflaRx NV Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
75.22M | 54.12M | - | 63k | -42.67M | -0.79 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
InflaRx NV News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IFRX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.37 | 1.46 | 1.26 | 1.37 | 130,874 | 0.02 | 1.46% |
1 Month | 1.52 | 1.68 | 1.24 | 1.47 | 210,763 | -0.13 | -8.55% |
3 Months | 1.57 | 1.92 | 1.24 | 1.56 | 242,718 | -0.18 | -11.46% |
6 Months | 1.73 | 2.11 | 1.14 | 1.53 | 320,989 | -0.34 | -19.65% |
1 Year | 4.91 | 5.20 | 1.14 | 2.50 | 270,854 | -3.52 | -71.69% |
3 Years | 3.74 | 7.2499 | 0.7762 | 3.91 | 667,781 | -2.35 | -62.83% |
5 Years | 46.99 | 47.29 | 0.7762 | 4.26 | 706,103 | -45.60 | -97.04% |
InflaRx NV Description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |